Name : Cynomolgus CD30/TNFRSF8 Protein
Product Source :
Recombinant Cynomolgus CD30/TNFRSF8 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Ala27-Pro394.[Accession | A0A2K5VW07]
Molecular Weight :
The protein has a predicted MW of 39.86 kDa. Due to glycosylation, the protein migrates to 75-105 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Cynomolgus CD30 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Cynomolgus CD30 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Cynomolgus CD30, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-CD30 Antibody, hFc Tag with the EC50 of 10.5ng/ml determined by ELISA.
Background :
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin’s disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin’s lymphomas (NHLs).
Synonyms :
CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1
References & Citations :
(1) Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. PMID: 19760074.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
FAK1 ProteinPurity & Documentation
B7-H6 ProteinBiological Activity
Popular categories:
IL-6R/CD126
Serpin B11